Cross-reactive epitope for multiple sclerosis
AssigneeThe Board of Trustees of the Leland Stanford Junior University
InventorsNaresha Saligrama, Mark M. Davis
Life of this patent
Estimating the term…
Abstract
Provided herein are methods and compositions for diagnosis and treatment of multiple sclerosis. Compositions and methods are provided, relating to novel peptides involved in autoimmune disease. In the experiments described herein, an unbiased approach was used to screen pathogenic CD4+ T cells from patients with multiple sclerosis (MS), and to determine the antigenic specificity of the T cell receptors (TCR) expressed by these pathogenic cells.
Claims20
An isolated cross-reactive peptide that comprises or consists of an amino acid sequence of any one of ATFTSYRSWYLA (SEQ ID NO:
- 1), ANYGKARSWYLK (SEQ ID NO:2), IDRHMYHSYLK (SEQ ID NO:3), DKGQQYRNWFLK (SEQ ID NO:
- 4), SEQ ID NOs:
- 23-75, or a variant thereof comprising up to 3 amino acid substitutions or deletions, wherein the isolated cross-reactive peptide is up to 40 amino acids in length.
An isolated T cell receptor (TCR) peptide that comprises or consists of an amino acid sequence set forth in any of SEQ ID NO:
- 5, 7-22 or 76, 78-83 or a variant thereof comprising up to 3 amino acid substitutions or deletions wherein the isolated cross-reactive peptide is up to 40 amino acids in length.
Dependencies are inferred from the claim text.